TrialRMD open2024

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial.

Iain B McInnes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.